Home Cart Sign in  
Chemical Structure| 861875-60-7 Chemical Structure| 861875-60-7

Structure of NVP-BAW2881
CAS No.: 861875-60-7

Chemical Structure| 861875-60-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAW2881 is an inhibitor of vascular endothelial growth factor (VEGF) with IC50s of 1.0 nM-4.3 nM against VEGFR1, 2, 3 and also inhibits PDGFRβ, c-Kit, and RET.

Synonyms: BAW2881

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NVP-BAW2881

CAS No. :861875-60-7
Formula : C22H15F3N4O2
M.W : 424.38
SMILES Code : O=C(NC1=CC=CC(C(F)(F)F)=C1)C2=C3C=CC(OC4=NC(N)=NC=C4)=CC3=CC=C2
Synonyms :
BAW2881
MDL No. :MFCD30343850
InChI Key :MLLQJNIKDWEEFT-UHFFFAOYSA-N
Pubchem ID :16004702

Safety of NVP-BAW2881

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of NVP-BAW2881

RTK

Isoform Comparison

Biological Activity

Target
  • VEGFR1

    hVEGFR1, IC50:820 nM

  • VEGFR3

    hVEGFR3, IC50:420 nM

  • VEGFR2

    hVEGFR2, IC50:9 nM

    mVEGF2, IC50:165 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Lymphatic Endothelial Cells (LECs) 1 nM to 1 μM 72 h NVP-BAW2881 significantly inhibited VEGF-A and VEGF-C-induced proliferation, migration, and tube formation in LECs. PMC2438303
Human Umbilical Vein Endothelial Cells (HUVECs) 1 nM to 1 μM 72 h NVP-BAW2881 significantly inhibited VEGF-A-induced proliferation, migration, and tube formation in HUVECs. PMC2438303
Lymphatic endothelial cells (LECs) 1 nM - 1 μM 72 h NVP-BAW2881 significantly inhibited VEGF-A and VEGF-C-induced proliferation of LECs. PMC2438303
Human umbilical vein endothelial cells (HUVECs) 1 nM - 1 μM 72 h NVP-BAW2881 significantly inhibited VEGF-A-induced proliferation of HUVECs. PMC2438303

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Transgenic mouse model of psoriasis Oral 25 mg/kg Once daily for 14 days NVP-BAW2881 significantly reduced psoriasis-like skin inflammation, decreased the number of blood and lymphatic vessels, and normalized the epidermal architecture. PMC2438303
Mice and domestic pigs K14/VEGF-A transgenic mouse model and UVB-induced skin inflammation model Oral and topical administration Oral 25 mg/kg/day, topical 0.1% to 0.5% Oral once daily, topical twice daily for 14 days NVP-BAW2881 significantly reduced skin inflammation symptoms, including decreased numbers of blood and lymphatic vessels, reduced leukocyte infiltration, and normalized epidermal architecture. PMC2438303

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.78mL

2.36mL

1.18mL

23.56mL

4.71mL

2.36mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories